HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

Oesophageal cancer is the sixth most common cause of cancer-related death worldwide
and is therefore a major global health challenge. The two major subtypes of oesophageal …

Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have
thus far been disappointing owing to a lack of robust stratification methods. Whole-genome …

Background Definitive chemoradiotherapy (CRT) is an alternative to surgery for the curative
treatment of oesophageal carcinoma. The SCOPE1 trial aimed to investigate the addition of …

We have recently gained unprecedented insight into genetic factors that determine risk for
Barrett's esophagus (BE) and progression to esophageal adenocarcinoma (EA). Next …

Aberrant activation of the HGF/MET signaling axis has been strongly implicated in the
malignant transformation and progression of gastroesophageal cancer (GEC). MET receptor …

Receptor tyrosine kinases (RTKs) are in the focus of targeted therapy for epithelial tumors.
Our study addressed the role of EGFR, HER2 and HER3 expression and dimerization in …

Esophageal adenocarcinoma (EAC) is a highly heterogeneous disease, dominated by large-
scale genomic rearrangements and copy number alterations. Such characteristics have …

Esophageal adenocarcinoma (EAC) is the eighth most common cancer worldwide, and
approximately 15% of patients survive 5 years. Reflux disease (GERD) and Barrett's …

Background Fibroblast growth factor receptor 2 (FGFR2) genetic alterations lead to tumor
cell proliferation in various types of cancer. We hypothesized that FGFR2 amplification is …